Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy	Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm	Recruiting	Phase 3	2026-02-24		NCT07414758

5 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Ruijin Hospital	454
Shanghai Cancer Hospital, China	15
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	141
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University	77
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine	91

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Shanghai General Hospital,Shanghai Jiao Tong University School of Medicine	Shanghai	China	3